U.S. Markets close in 35 mins
  • S&P 500

    3,580.42
    +22.88 (+0.64%)
     
  • Dow 30

    29,609.36
    +345.88 (+1.18%)
     
  • Nasdaq

    11,893.08
    +38.12 (+0.32%)
     
  • Russell 2000

    1,785.34
    +1.21 (+0.07%)
     
  • Crude Oil

    42.17
    +0.43 (+1.03%)
     
  • Gold

    1,869.60
    +8.10 (+0.44%)
     
  • Silver

    24.23
    +0.18 (+0.74%)
     
  • EUR/USD

    1.1862
    -0.0014 (-0.1186%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    23.70
    +0.59 (+2.55%)
     
  • GBP/USD

    1.3291
    +0.0038 (+0.2858%)
     
  • USD/JPY

    103.8280
    +0.0570 (+0.0549%)
     
  • BTC-USD

    18,393.94
    -60.81 (-0.33%)
     
  • CMC Crypto 200

    363.81
    +2.39 (+0.66%)
     
  • FTSE 100

    6,351.45
    +17.10 (+0.27%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

CERN vs. TRHC: Which Stock Should Value Investors Buy Now?

Zacks Equity Research
·2 min read

Investors with an interest in Medical Info Systems stocks have likely encountered both Cerner (CERN) and Tabula Rasa Healthcare (TRHC). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Cerner and Tabula Rasa Healthcare are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. This means that CERN's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

CERN currently has a forward P/E ratio of 25.30, while TRHC has a forward P/E of 85.67. We also note that CERN has a PEG ratio of 1.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. TRHC currently has a PEG ratio of 2.38.

Another notable valuation metric for CERN is its P/B ratio of 5.66. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, TRHC has a P/B of 7.52.

These are just a few of the metrics contributing to CERN's Value grade of B and TRHC's Value grade of D.

CERN sticks out from TRHC in both our Zacks Rank and Style Scores models, so value investors will likely feel that CERN is the better option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cerner Corporation (CERN) : Free Stock Analysis Report
 
Tabula Rasa Healthcare Inc. (TRHC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research